In the latest trading session, 0.64 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company’s beta touched -1.17. With the company’s most recent per share price at $8.06 changed hands at -$0.12 or -1.53% at last look, the market valuation stands at $358.26M. CADL’s current price is a discount, trading about -81.14% off its 52-week high of $14.60. The share price had its 52-week low at $1.16, which suggests the last value was 85.61% up since then. When we look at Candel Therapeutics Inc’s average trading volume, we note the 10-day average is 1.6 million shares, with the 3-month average coming to 3.58 million.
Analysts gave the Candel Therapeutics Inc (CADL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CADL as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Candel Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL was in red as seen in intraday trades today. With action -12.63%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -7.20%, with the 5-day performance at -12.63% in the red. However, in the 30-day time frame, Candel Therapeutics Inc (NASDAQ:CADL) is 74.73% up. Looking at the short shares, we see there were 1.78 million shares sold at short interest cover period of 7.72 days.
Candel Therapeutics Inc (CADL) estimates and forecasts
Data shows that the Candel Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 32.05% over the past 6 months, a -21.37% in annual growth rate that is considerably lower than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -46.75%. The 2025 estimates are for Candel Therapeutics Inc earnings to decrease by -21.37%.
CADL Dividends
Candel Therapeutics Inc is expected to release its next quarterly earnings report in February.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 30.39% of Candel Therapeutics Inc shares while 22.53% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 32.37%. There are 22.53% institutions holding the Candel Therapeutics Inc stock share, with NORTHPOND VENTURES, LLC the top institutional holder. As of 2024-06-30, the company held 6.628% of the shares, roughly 1.94 million CADL shares worth $12.0 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. With 511.78 shares estimated at $4.02 million under it, the former controlled 1.58% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.40% of the shares, roughly 453.81 shares worth around $3.56 million.
